Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage

The Journal of Immunology : Official Journal of the American Association of Immunologists
Tanja Schneider-MerckMichael Dechant

Abstract

Ab-dependent cellular cytotoxicity (ADCC) is usually considered an important mechanism of action for immunotherapy with human IgG1 but not IgG2 Abs. The epidermal growth factor receptor (EGF-R) Ab panitumumab represents the only human IgG2 Ab approved for immunotherapy and inhibition of EGF-R signaling has been described as its principal mechanism of action. In this study, we investigated effector mechanisms of panitumumab compared with zalutumumab, an EGF-R Ab of the human IgG1 isotype. Notably, panitumumab was as effective as zalutumumab in recruiting ADCC by myeloid effector cells (i.e., neutrophils and monocytes) in contrast to NK cell-mediated ADCC, which was only induced by the IgG1 Ab. Neutrophil-mediated tumor cell killing could be stimulated by myeloid growth factors and was triggered via FcgammaRIIa. Panitumumab-mediated ADCC was significantly affected by the functional FcgammaRIIa-R131H polymorphism and was induced more effectively by neutrophils from FcgammaRIIa-131H homozygous donors than from -131R individuals. This polymorphism did not affect neutrophil ADCC induced by the IgG1 Ab zalutumumab. The in vivo activity of both Abs was assessed in two animal models: a high-dose model, in which signaling inhibition is a...Continue Reading

References

May 1, 1991·Journal of Leukocyte Biology·J G van de Winkel, C L Anderson
Nov 1, 1987·The Journal of Experimental Medicine·M BrüggemannM S Neuberger
Mar 31, 2000·Nature Medicine·A N Houghton, D A Scheinberg
Mar 13, 2001·Annual Review of Immunology·J V Ravetch, S Bolland
Mar 20, 2001·Critical Reviews in Oncology/hematology·X D YangC G Davis
May 31, 2002·Expert Opinion on Investigational Drugs·Roy S Herbst
Jul 1, 2004·Blood·Guillaume CartronPhilippe Solal-Celigny
Sep 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Wim K BleekerPaul W H I Parren
Apr 20, 2006·Nature Reviews. Immunology·Paul J Carter
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nai-Kong V CheungRichard Gorlick
Feb 13, 2007·Current Opinion in Immunology·Falk Nimmerjahn, Jeffrey V Ravetch
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wu ZhangHeinz-Josef Lenz
Aug 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michael DechantThomas Valerius
Aug 31, 2007·Expert Opinion on Biological Therapy·Roy Jefferis
Nov 13, 2007·Drug Discovery Today·John R DesjarlaisSeung Y Chu
Dec 18, 2007·Expert Opinion on Biological Therapy·Marjolein van Egmond
Mar 7, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Matthias PeippThomas Valerius
Mar 14, 2008·The New England Journal of Medicine·Fortunato Ciardiello, Giampaolo Tortora
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonino MusolinoAndrea Ardizzoni
Apr 23, 2008·Proceedings of the National Academy of Sciences of the United States of America·Jeroen J Lammerts van BuerenPaul W H I Parren
Jul 1, 2008·Current Opinion in Immunology·Matthias PeippThomas Valerius
Jul 1, 2008·Current Opinion in Immunology·Ronald P Taylor, Margaret A Lindorfer
Aug 15, 2008·Biotechnology Journal·Sigrid R RuulsPaul W H I Parren
Nov 11, 2008·Experimental Cell Research·Karl R Schmitz, Kathryn M Ferguson
Jan 24, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric BibeauFlorence Boissière-Michot
Feb 28, 2009·Nature Reviews. Drug Discovery·Roy Jefferis
Mar 24, 2009·Lancet·Louis M WeinerSoldano Ferrone

❮ Previous
Next ❯

Citations

Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B Vermorken, P Specenier
Mar 20, 2012·Carcinogenesis·Zvi G Fridlender, Steven M Albelda
Nov 15, 2012·Chemotherapy Research and Practice·Jeffery S Russell, A Dimitrios Colevas
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert L FerrisSoldano Ferrone
Dec 12, 2012·PloS One·Mirko CorteseMarcello Merola
Feb 28, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raghvendra M SrivastavaRobert L Ferris
Nov 18, 2015·Expert Opinion on Drug Metabolism & Toxicology·Louisa LoTimothy J Price
Jun 18, 2011·Expert Opinion on Biological Therapy·Rodrigo Dienstmann, Enriqueta Felip
Feb 27, 2016·Signal Transduction and Targeted Therapy·Sasha BogdanovichJayakrishna Ambati
Jan 29, 2016·Journal of Immunology Research·Eileen Uribe-Querol, Carlos Rosales
Jul 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S TrivediR L Ferris
Feb 23, 2012·Scientific Reports·David N A MekhaielRichard J Pleass
Apr 29, 2014·Expert Opinion on Drug Safety·Stefan StremitzerHeinz-Josef Lenz
Sep 28, 2016·Scientific Reports·Wei Hseun YeapSiew Cheng Wong
Dec 16, 2016·Immunology and Cell Biology·Bryan C Barnhart, Michael Quigley
Dec 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irene Y CheungNai-Kong V Cheung
Jun 16, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas Valerius
Apr 3, 2014·Journal of Ethnopharmacology·Hong-Xiang SunFeng-Yang Chen
Feb 14, 2017·Cancer Treatment Reviews·Rosalyn A JuergensAaron R Hansen
Mar 5, 2017·Immunological Reviews·Hanke L MatlungTimo K van den Berg
Mar 25, 2017·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hassan Izzedine, Mark A Perazella
Nov 22, 2015·International Immunopharmacology·Bisong ZhangZhenxiang Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.